Search clinical trials for: CHF 5993 200/6/12.5 µg

Total 43 results

Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

COPD

Belgium
Chiesi Farmaceutici S.p.A.

Completed

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA (TRIMARAN)

Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (TRIGGER)

Asthma

Argentina, Belarus, Bulgaria, Czechia, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Turkey, Ukraine, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Asthma

Belgium
Chiesi Farmaceutici S.p.A.
SGS S.A.

Recruiting

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Asthma

Belgium
Statens Serum Institut

Completed

Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers

Tuberculosis

Netherlands
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Completed

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)

COPD (Chronic Obstructive Pulmonary Disease)

China, Korea, Republic of, Taiwan
INSYS Therapeutics Inc

Withdrawn

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Acute Pain

United States
Chiesi Farmaceutici S.p.A.

Completed

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (ADO pMDI)

Asthma

Poland
Chiesi Farmaceutici S.p.A.

Recruiting

Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) (TRECOS)

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Terminated

A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR) (FAIR)

Chronic Obstructive Pulmonary Disease

Netherlands
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Italy, Germany, Hungary
Chiesi Farmaceutici S.p.A.

Completed

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)

Chronic Obstructive Pulmonary Disease

China
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Chronic Obstructive Pulmonary Disease

France
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

Chronic Obstructive Pulmonary Disease

Hungary
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (Neptune)

Asthma

Poland
Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)

Asthma

Bulgaria, Germany, Italy, Netherlands, Poland
Chiesi Farmaceutici S.p.A.

Completed

Triple in Asthma Dose Finding (Triskel)

Asthma

Bulgaria, Germany, Hungary, Italy, Poland, United Kingdom
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Chiesi Farmaceutici S.p.A.

Completed

A Study in Patients With Chronic Obstructive Pulmonary Disease (FUTURE)

Chronic Obstructive Pulmonary Disease

Italy
EMS

Recruiting

Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma

Asthma

Brazil
Chiesi Farmaceutici S.p.A.

Completed

A Study in Patients With Asthma (NELSON)

Asthma

Italy
University Hospital, Antwerp
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients

Asthma

Belgium
Auro Vaccines LLC
United States Department of Defense; Accelovance

Completed

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

Ebola Virus Disease

United States
Nektar Therapeutics

Recruiting

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Non-Hodgkin Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma

United States
Genexine, Inc.

Completed

Phase I Study GX-G3 in Healthy Subjects (GX-G3)

Healthy

Korea, Republic of
University of Michigan Rogel Cancer Center
Rush University Medical Center

Completed

Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer

Pancreatic Cancer

United States
Eurofarma Laboratorios S.A.

Not yet recruiting

Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil (FORASMA)

Moderate Asthma

Brazil
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
Zuyderland Medisch Centrum
AtriCure, Inc.

Recruiting

Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (ICE)

Funnel Chest | Pectus Excavatum

Netherlands
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Small Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
Charite University, Berlin, Germany

Unknown

Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases (ASTRAD)

Autoimmune Diseases

Germany
Research in Real-Life Ltd
Chiesi Farmaceutici S.p.A.

Completed

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management (Fos/Ser_switch)

Asthma

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Ph-Like Acute Lymphoblastic Leukemia

United States
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Completed

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Chronic Lymphocytic Leukemia (CLL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chemotherapy-sensitive Lymphoma | Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma | Acute Biphenotypic Leukemia (ABL) | Acute Undifferentiated Leukemia (AUL)

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells Present

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
University of Washington
Genentech, Inc.

Suspended

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia

Search clinical trials for: CHF 5993 200/6/12.5 µg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations